Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a open-label PK, safety, and immunogenicity study of subcutaneous casirivimab + imdevimab in high-risk pediatric subjects under 12 years
2021-004590-30Phase 2
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of casirivimab and imdevimab in coronavirus disease 2019 (COVID-19), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Serum concentrations of casirivimab + imdevimab over time.
02
Drugs
casirivimabimdevimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-004590-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004590-30.